Table III.
Sensitivity, specificity and likelihood ratio of different scores in patients with low-grade and clinically suspected myelodysplastic syndrome (MDS)
| Score | MDS type | Sensitivity (%) | Specificity (%) | Likelihood ratio for positive results |
|---|---|---|---|---|
| Ogata score | Low-grade (LG)-MDS (n=21) | 66.6 | 94.4 | 11.89 |
| All clinically suspected MDS (n=44) | 76.4 | 94.4 | 13.64 | |
| Aberrant antigen and pattern analysis score | LG-MDS (n=21) | 80.9 | 94.4 | 14.4 |
| All clinically suspected MDS (n=44) | 88.2 | 94.4 | 15.75 | |
| Combined score | LG-MDS (n=21) | 95.2 | 88.8 | 8.5 |
| All clinically suspected MDS (n=44) | 97 | 88.8 | 8.6 |